We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | 장 마감 후 (AMC) | $-1.06 | — | — | $858.9K | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.81 | — | — | $695K | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-1.74 | — | — | $5.85M |
Consensus PT $58.43 · 14 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 13. | Wells Fargo | — | 의견 유지 | Overweight → Overweight | — | Wells Fargo: Overweight |
| 2026. 05. 08. | Barclays | — | 의견 유지 | Overweight → Overweight | — | Barclays: Overweight |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-1.1 | — | — | $2.65M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Stored first · Google News · Yahoo Finance (English)
Wall Street analysts see a 76.42% upside in Celldex (CLDX): Can the stock really move this high? - MSN
Wall Street analysts see a 76.42% upside in Celldex (CLDX): Can the stock really move this high? MSN
Celldex Therapeutics stock (US15117B1035): Nasdaq-listed biotech trades quietly ahead of next cataly - AD HOC NEWS
Celldex Therapeutics stock (US15117B1035): Nasdaq-listed biotech trades quietly ahead of next cataly AD HOC NEWS
Celldex Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Celldex Therapeutics | SCHEDULE 13G/A: Others Moomoo
[Latest] Global Cholera Vaccine Market Size/Share Worth USD 649 Million by 2035 at a 7.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Kynam Capital reports 5.84M-share (8.77%) position in Celldex (CLDX) - Stock Titan
Kynam Capital reports 5.84M-share (8.77%) position in Celldex (CLDX) Stock Titan
Bellevue (CLDX) holds 1.2M shares (1.5%) — files Amendment No.1 - Stock Titan
Bellevue (CLDX) holds 1.2M shares (1.5%) — files Amendment No.1 Stock Titan